MetLife authorized a share repurchase program on August 5, 2026. The announcement covers a buyback plan — an authorization to repurchase the company's own shares. An authorization is not a purchase; it gives the company permission to buy back stock, but does not confirm any shares have yet been acquired.
For holders, a buyback program reduces the share count over time if and when executed, spreading earnings across fewer shares. For short sellers, the picture is calm: short interest stands at 2.4% of free float, with a cost to borrow of just 0.46% and availability remaining loose, leaving no meaningful squeeze pressure at current levels.
Across 299 comparable buyback authorizations in the wider market, shares moved an average of 1.4% over the following five trading days, with 62.5% moving in a positive direction.
See the live data behind this article on ORTEX.
Open MET on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
